EW Weekly, March 6, 2020

- FDA approves first intracameral, sustained-release bimatoprost implant
- Study: SARS-CoV-2 may be present in coronavirus patients with conjunctivitis
- Novartis issues safety update for wet AMD drug Beovu
- DREAM extension study: Halting of omega-3 supplementation did not lead to differing clinical results for dry eye
- Second Phase 3 results with YUTIQ focus on reducing flares in chronic non-infectious uveitis
- TOBRADEX ST launched by Eyevance
- In a systematic review and meta-analysis, autologous serum tears were found to be an effective treatment for dry eye disease, reported L. Wang and coresearchers. Their study included five databases that were searched for relevant randomized controlled trials comparing autologous serum eye drops versus artificial tears. The OSDI, Schirmer I test, tear breakup time, and fluorescein and rose bengal staining were used to evaluate efficacy. Seven randomized controlled trials were found with 267 subjects. Subject age in most studies was 50 years, with a treatment duration of about 8 weeks. The OSDI was lower after autologous serum treatment compared with artificial tears (mean difference, –10.75 points). No difference was found in the Schirmer I test after treatment between the two groups (mean difference, 1.68 points). Tear breakup time in the autologous serum group was longer than that in the artificial tear group (4.53 points). No statistically significant difference was found in the fluorescein staining scores between the two groups (–2.53 points). Rose bengal staining score in the autologous serum group was slightly lower than that in the artificial tear group (mean difference, –0.78). More randomized controlled trials with large samples and longer follow-up are needed to further target the role of autologous serum to manage dry eye disease, the researchers concluded. The study is published in Ophthalmic Research.
- There were non-significant differences among nine formulas used for multifocal IOL implantation candidates, reported Joaquín Fernández, MD, and coresearchers. A method to make it easier to detect accuracy deficiencies of any IOL power calculation formula was used in the retrospective, observational case series and was tested among the nine formulas. The first stage of the study included 3,519 eyes from cataract surgery candidates. Frequency distributions were computed for axial length, anterior chamber depth, lens thickness, white-to-white, and mean corneal radius. Resulting data for each parameter were 5th , 25th, and 75th, and 95th percentile, allowing researchers to define a corresponding normality range. In the study’s second stage, a graphic representation method was tested for nine formulas in 70 eyes slated for cataract surgery with multifocal IOL implantation. The normality ranges were 22.84 to 24.42 mm for axial length, 2.86 to 3.39 mm for anterior chamber depth, 4.36 to 4.88 mm for lens thickness, 11.64 to 12.19 mm for white-to-white, and 7.52 to 7.87 mm for mean corneal radius. The graphical method showed less accuracy in ±0.50 D for anterior chamber depths from 2.46 to 2.85 mm for several formulas (P<0.05). The research appears in the Journal of Cataract & Refractive Surgery.
This issue of EyeWorld Weekly was edited by Stacy Jablonski and Vanessa Caceres.
EyeWorld Weekly (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery (ASCRS), is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: Eric Donnenfeld, MD, Chief Medical Editor; Rosa Braga-Mele, MD, Cataract Editor; Clara Chan, MD, Cornea Editor; Nathan Radcliffe, MD, Glaucoma Editor; and Vance Thompson, MD, Refractive Editor
For sponsorship opportunities or membership information, contact: ASCRS • 4000 Legato Rd. • Suite 700 • Fairfax, VA 22033 • Phone: 703-591-2220 • Fax: 703-591-0614 • Email: ASCRS Opinions expressed in EyeWorld Weekly do not necessarily reflect those of ASCRS. Mention of products or services does not constitute an endorsement by ASCRS.
Click here to view our Legal Notice.
Copyright 2021, EyeWorld News Service, a division of ASCRSMedia. All rights reserved.